Drug Search Results
More Filters [+]

AZD-7503

Alternative Names: azd-7503, azd 7503, azd7503, ION455, ION-455
Latest Update: 2024-02-09
Latest Update Note: Clinical Trial Update

Product Description

ION455, also known as AZD7503, is an investigational antisense medicine designed for the treatment of nonalcoholic steatohepatitis (NASH). (Sourced from: https://www.ionispharma.com/ionis-innovation/pipeline/)

Mechanisms of Action: HSD17B13 Inhibitor

Novel Mechanism: Yes

Modality: Nucleic Acid

Route of Administration: Subcutaneous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for AZD-7503

Countries in Clinic: Japan, Puerto Rico, United States

Active Clinical Trial Count: 4

Highest Development Phases

Phase 1: Fatty Liver|Fatty Liver, Alcoholic|Healthy Volunteers|Hepatitis|Hepatitis, Alcoholic|Liver Diseases, Alcoholic|Non-alcoholic Steatohepatitis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

jRCT2071230075

P1

Recruiting

Fatty Liver, Alcoholic

2024-12-31

D9230C00003

P1

Active, not recruiting

Fatty Liver, Alcoholic|Liver Diseases, Alcoholic|Hepatitis, Alcoholic|Non-alcoholic Steatohepatitis

2024-03-04

21%

D9230C00002

P1

Recruiting

Hepatitis|Fatty Liver

2024-01-08

21%

D9230C00001

P1

Completed

Healthy Volunteers

2022-11-09

28%

Recent News Events